CStone Pharmaceuticals (2616.HK)

Name: CStone Pharmaceuticals Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-04-07

Latest Quarter

2026-04-07

Revenue

$24.7M

Net Income

-$135M

Operating Margin

-560.5%

Free Cash Flow

-$343M

Debt / Assets

49.1%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for CStone Pharmaceuticals (2616.HK).
Income Statement (Quarterly)	2026-04-07	2025-12-31	2025-06-30	2025-03-31
Revenue	24,725,500	216,459,408	24,725,500	24,725,500
Cost of Revenue	71,120,500	77,418,467	71,120,500	71,120,500
Gross Profit	-46,395,000	139,040,940	-46,395,000	-46,395,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	39,600,000	89,016,684	39,600,000	39,600,000
Operating Expenses	92,183,000	291,912,227	92,183,000	92,183,000
Operating Income	-138,578,000	-152,871,285	-138,578,000	-138,578,000
Interest Expense	0	6,257,824	2,910,500	0
Income Before Tax	-135,091,500	-151,190,798	-135,091,500	-135,091,500
Income Tax Expense	0	12,846,045	0	0
Net Income	-135,091,500	-164,036,844	-135,091,500	-135,091,500
Per Share
EPS	-0.10	-0.11	-0.10	-0.10
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for CStone Pharmaceuticals (2616.HK).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2023-06-30	2022-12-31
Revenue	262,605,892	407,205,000	463,842,000	0	481,363,000
Cost of Revenue	217,821,750	167,051,000	159,547,000	0	202,985,000
Gross Profit	44,784,141	240,154,000	304,295,000	0	278,378,000
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	162,766,499	166,943,000	248,065,000	0	390,476,000
Operating Expenses	466,208,430	331,846,000	304,295,000	0	1,181,886,000
Operating Income	-421,424,288	-91,692,000	-534,607,000	0	-832,272,000
Interest Expense	12,928,505	15,167,000	11,819,000	0	8,477,000
Income Before Tax	-412,966,988	-91,207,000	-367,234,000	0	-902,678,000
Income Tax Expense	12,725,888	0	0	0	61,929,000
Net Income	-425,692,877	-91,207,000	-367,234,000	0	-964,607,000
Per Share
EPS	-0.31	-0.07	-0.29	0.00	-0.82
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for CStone Pharmaceuticals (2616.HK).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	754,021,450	387,937,000	996,671,000	558,684,000
Short Term Investments	165,070,590	285,000,000	30,000,000	483,407,000
Net Receivables	33,825,464	130,875,000	172,438,000	77,133,000
Inventory	116,936,005	286,096,000	108,828,000	22,188,000
Total Current Assets	1,113,664,248	1,089,908,000	1,329,787,000	1,246,917,000
Property Plant Equipment	83,163,563	130,543,000	153,368,000	206,566,000
Goodwill and Intangibles	0	161,366,000	173,045,000	159,699,000
Total Assets	1,358,949,142	1,393,466,000	1,661,999,000	1,638,427,000
Liabilities
Account Payables	77,234,028	338,029,000	246,377,000	290,414,000
Short Term Debt	191,669,965	93,216,000	139,313,000	44,918,000
Total Current Liabilities	510,441,285	682,006,000	850,338,000	946,482,000
Long Term Debt	156,996,136	262,757,000	224,135,000	241,372,000
Total Liabilities	667,437,423	1,029,595,000	1,205,169,000	1,189,101,000
Shareholders Equity
Retained Earnings	0	-9,110,934,000	-9,019,727,000	-8,652,493,000
Total Shareholders Equity	617,032,868	363,871,000	456,830,000	449,326,000

Balance sheet annual history for CStone Pharmaceuticals (2616.HK).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	754,021,450	387,937,000	996,671,000	558,684,000	742,724,000
Short Term Investments	165,070,590	285,000,000	30,000,000	483,407,000	983,615,000
Net Receivables	33,825,464	130,875,000	172,438,000	77,133,000	0
Inventory	116,936,005	286,096,000	108,828,000	22,188,000	61,363,000
Total Current Assets	1,113,664,248	1,089,908,000	1,329,787,000	1,246,917,000	1,957,645,000
Property Plant Equipment	83,163,563	130,543,000	153,368,000	206,566,000	187,923,000
Goodwill and Intangibles	0	161,366,000	173,045,000	159,699,000	70,539,000
Total Assets	1,358,949,142	1,393,466,000	1,661,999,000	1,638,427,000	2,271,453,000
Liabilities
Account Payables	77,234,028	338,029,000	246,377,000	290,414,000	33,024,000
Short Term Debt	191,669,965	93,216,000	139,313,000	44,918,000	43,948,000
Total Current Liabilities	510,441,285	682,006,000	850,338,000	946,482,000	932,948,000
Long Term Debt	156,996,136	262,757,000	224,135,000	241,372,000	130,250,000
Total Liabilities	667,437,423	1,029,595,000	1,205,169,000	1,189,101,000	1,064,445,000
Shareholders Equity
Retained Earnings	0	-9,110,934,000	-9,019,727,000	-8,652,493,000	0
Total Shareholders Equity	617,032,868	363,871,000	456,830,000	449,326,000	1,207,008,000

Cash flow quarterly history for CStone Pharmaceuticals (2616.HK).
Cash Flow Statement (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-91,207,000	-367,234,000	-902,678,000	-1,920,100,000
Depreciation & Amortization	49,805,000	58,190,000	44,540,000	22,661,000
Stock Based Compensation	-2,811,000	36,993,000	142,062,000	222,671,000
Change in Working Capital	-165,897,000	-140,814,000	72,647,000	64,520,000
Operating Cash Flow	-343,181,000	-588,843,000	-612,469,000	-1,484,024,000
Investing Activities
Capital Expenditure	0	-65,047,000	-101,821,000	-149,136,000
Investments	0	-15,000	-101,821,000	-91,026,000
Investing Cash Flow	-247,679,000	619,605,000	365,119,000	-826,552,000
Financing Activities
Debt Repayment	-34,023,000	91,433,000	-32,000,000	-6,706,000
Common Stock Issued/Repurchased	0	341,824,000	2,529,000	16,830,000
Dividends Paid	0	0	0	0
Financing Cash Flow	-12,896,000	388,355,000	28,467,000	92,304,000
Summary
Free Cash Flow	-343,181,000	-653,890,000	-714,290,000	-1,633,160,000
Net Change in Cash	-608,734,000	437,987,000	-184,040,000	-2,281,824,000

Cash flow annual history for CStone Pharmaceuticals (2616.HK).
Cash Flow Statement (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Operating Activities
Net Income	-91,207,000	-367,234,000	-902,678,000	-1,920,100,000	-1,220,999,000
Depreciation & Amortization	49,805,000	58,190,000	44,540,000	22,661,000	14,801,000
Stock Based Compensation	-2,811,000	36,993,000	142,062,000	222,671,000	356,023,000
Change in Working Capital	-165,897,000	-140,814,000	72,647,000	64,520,000	185,978,000
Operating Cash Flow	-343,181,000	-588,843,000	-612,469,000	-1,484,024,000	-508,070,000
Investing Activities
Capital Expenditure	0	-65,047,000	-101,821,000	-149,136,000	-71,446,000
Investments	0	-15,000	-101,821,000	-91,026,000	-67,039,000
Investing Cash Flow	-247,679,000	619,605,000	365,119,000	-826,552,000	1,180,732,000
Financing Activities
Debt Repayment	-34,023,000	91,433,000	-32,000,000	-6,706,000	-1,580,000
Common Stock Issued/Repurchased	0	341,824,000	2,529,000	16,830,000	1,339,128,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	-12,896,000	388,355,000	28,467,000	92,304,000	1,389,429,000
Summary
Free Cash Flow	-343,181,000	-653,890,000	-714,290,000	-1,633,160,000	-579,516,000
Net Change in Cash	-608,734,000	437,987,000	-184,040,000	-2,281,824,000	1,898,112,000